December 20, 2024
TOPLINE: SAN DIEGO — Despite its significantly higher acquisition costs, lisocabtagene maraleucel (liso-cel, Breyanzi) demonstrated better survival and quality of life as well as fewer time […]
December 19, 2024
The US Food and Drug Administration (FDA) has approved remestemcel-L (Ryoncil, Mesoblast Ltd), an allogeneic bone marrow‒derived mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-vs-host […]
December 19, 2024
In recent years, hypofractionated radiation has eclipsed conventionally fractionated radiation as the preferred treatment option for a range of cancer types, including early breast, prostate, lung, […]
December 19, 2024
Patients with mantle cell lymphoma (MCL) who show undetectable minimal residual disease (MRD) after initial treatment with chemotherapy show no significant overall or progression-free survival benefit […]
December 19, 2024
Clinicians frequently reach out to Catherine Varney, DO, asking if it’s safe to prescribe glucagon-like peptide 1 receptor agonists (GLP-1 RAs) to patients with thyroid disorders, […]
December 19, 2024
SAN ANTONIO — A machine learning model, which incorporates both clinical and genomic factors, helps predict which patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor […]
December 18, 2024
The US Food and Drug Administration (FDA) has approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for the treatment of adults with ALK-positive locally advanced or metastatic non-small […]
December 18, 2024
SAN ANTONIO — The randomized phase 3 ZEST trial, which was aimed at evaluating niraparib (Zejula) for prevention or delay of breast cancer recurrence in patients […]
December 18, 2024
In the treatment of relapsed or refractory follicular lymphoma (R/R FL), the addition of tafasitamab to a standard 2-drug combination of lenalidomide and rituximab (len+R) significantly […]